Wednesday, 14 Nov 2018

You are here

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Nucala, an interleukin-5 antagonist monoclonal antibody, was previously approved in 2015 to treat severe asthma with an eosinophilic phenotype.  The current approval occurs because of an FDA priority review through the orphan drug program. Orphan drug designation provides incentives to assist and encourage the development of drugs for rare diseases.

Evidence for the efficacy of mepolizumab was established in a NEJM report (N Engl J Med 2017; 376:1921-1932) published in May 18, 2017.  This was a 52 week study of 136 patients with relapsing or refractory EGPA patients (on stable doses of steroids) who were given either 300 mg of mepolizumab or placebo every 4 weeks, for a year. The mepolizumab group had more remissions at both week 36 and week 48 (32% vs. 3%), had a 50% lower annualized relapse rate and more patients in the mepolizumab group (18%) were able to discontinue prednisone.

Although only half the participants treated with mepolizumab had protocol-defined remission, this novel biologic intervention represents a new and significant advance in the treatment of EGPA.

Nucala is administered as 300mg once every four weeks by subcutaneous injection

The most common adverse reactions associated with Nucala in clinical trials included headache, injection site reaction, back pain, and fatigue. There are warnings about the risk of herpes zoster, helminthic infections and avoidance during acute bronchospasm or status asthmaticus.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.